Device Trial Radar · NCT00277069
Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jan 7, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
May 2000
Primary completion
Mar 2005
Study completion Mar 2006
Sponsor
- Lead sponsor
- University of New MexicoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1\. Determine the response rate with this regimen in an anthracycline and taxane resistant cohort of patients.
Conditions
- Breast
- Cancer
Interventions
CarboplatinDrug
Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
CapecitabineDevice
Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
VinorelbineDrug
Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measurable disease: Bidimensionally measurable lesions with clearly defined margins by 1) palpation with both diameters greater than 1 cm, 2) CT, MRI with both diameters greater than the distance between cuts of the imaging study.Time frame: disease progression or unacceptable toxicities
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of New Mexico
Albuquerque, New Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.